VYNE Therapeutics Inc. announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference.
BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference.
Presentation details can be found below.
| Barclays Global Healthcare Conference | |
| Day: | Tuesday, March 9, 2021 |
| Time: | 8:00am Eastern Time |
| Format: | Fireside chat |
| Webcast Link: | https://kvgo.com/2021-global-healthcare-conference/vyne-therapeutics-2021 |
| H.C. Wainwright Global Life Sciences Conference | |
| Day & Time: | On demand, beginning 7:00am Eastern Time, Tuesday, March 9, 2021 |
| Format: | Fireside chat |
| Webcast Link: | https://journey.ct.events/view/7534c623-91e5-4fa6-9d64-6dbed8781b9a |
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI® (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at AMZEEQ.com and ZILXI’s Full Prescribing Information at ZILXI.com.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
CONTACT:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com
Andrew Saik
Chief Financial Officer
VYNE Therapeutics
908-731-6180
Andrew.Saik@vynetx.com
